- Home
- CNTB vs LNSR Comparison
CNTB vs LNSR Comparison
Compare CNTB & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | LNSR |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.1M | 142.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNTB | LNSR |
|---|---|---|
| Price | $2.25 | $11.86 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | $8.50 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 502.0K | 48.1K |
| Earning Date | 03-31-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $762,000.00 | ★ $59,141,000.00 |
| Revenue This Year | N/A | $19.55 |
| Revenue Next Year | $38,289.22 | $35.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.02 |
| 52 Week Low | $0.51 | $7.13 |
| 52 Week High | $3.28 | $17.31 |
Technical Indicators
Market Signals| Indicator | CNTB | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 64.67 |
| Support Level | $2.27 | $11.00 |
| Resistance Level | $2.56 | $11.63 |
| Average True Range (ATR) | 0.19 | 0.40 |
| MACD | -0.07 | 0.20 |
| Stochastic Oscillator | 26.19 | 89.47 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About LNSR LENSAR Inc.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.